Now approved in EU

Defitelio® (defibrotide) 
The European Commission has granted a Marketing Authorization for Defitelio® (defibrotide) for the treatment of severe hepatic veno-occlusive disease (sVOD) in adults and children undergoing hematopoietic stem cell transplantation therapy.

 

Defibrotide is marketed in E.U. as Defitelio® - Learn more

In focus

Gentium S.p.A. is a
Jazz Pharmaceuticals company.

To learn more about Jazz Pharmaceuticals, click here

Product Pipeline

Defibrotide is an investigational drug for the prevention and treatment of VOD. The efficacy of defibrotide to treat hepatic VOD in hematopoietic stem cell transplantation (HSCT) patients is supported by data from a multi-center Phase III historically controlled trial, evaluating Defibrotide for the treatment of severe VOD, a Phase II dose finding study and interim data reported from the ongoing Phase III expanded access U.S. 

Product Pipeline

General News

Financial News

Gentium S.p.A. - P.IVA n. 02098100130

Medical Information

For any medical information enquiries please contact:
Email:medical-enquiries@gentium.it
Tel: +39 031 5373 112